ROLE of IGF-1 system in the modulation of longevity: Controversies and new insights from a centenarians' perspective by Vitale, G. (Giovanni) et al.
REVIEW
published: 01 February 2019
doi: 10.3389/fendo.2019.00027
Frontiers in Endocrinology | www.frontiersin.org 1 February 2019 | Volume 10 | Article 27
Edited by:
Antonio Aversa,
Università degli Studi Magna Græcia
di Catanzaro, Italy
Reviewed by:
Giuseppe Pasqualetti,
University of Pisa, Italy
Marian Beekman,
Leiden University Medical Center,
Netherlands
*Correspondence:
Giovanni Vitale
giovanni.vitale@unimi.it
Specialty section:
This article was submitted to
Endocrinology of Aging,
a section of the journal
Frontiers in Endocrinology
Received: 21 October 2018
Accepted: 15 January 2019
Published: 01 February 2019
Citation:
Vitale G, Pellegrino G, Vollery M and
Hofland LJ (2019) ROLE of IGF-1
System in the Modulation of
Longevity: Controversies and New
Insights From a Centenarians’
Perspective. Front. Endocrinol. 10:27.
doi: 10.3389/fendo.2019.00027
ROLE of IGF-1 System in the
Modulation of Longevity:
Controversies and New Insights
From a Centenarians’ Perspective
Giovanni Vitale 1,2*, Giuseppe Pellegrino 3, Maria Vollery 4 and Leo J. Hofland 5
1 Laboratorio Sperimentale di Ricerche di Neuroendocrinologia Geriatrica ed Oncologica, Istituto Auxologico Italiano
IRCCS, Milan, Italy, 2Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 3 Faculty of
Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, 4 ASP Redaelli Golgi, Milan, Italy, 5Division Endocrinology,
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
Human aging is currently defined as a physiological decline of biological functions in
the body with a continual adaptation to internal and external damaging. The endocrine
system plays a major role in orchestrating cellular interactions, metabolism, growth, and
aging. Several in vivo studies from worms to mice showed that downregulated activity
of the GH/IGF-1/insulin pathway could be beneficial for the extension of human life
span, whereas results are contradictory in humans. In the present review, we discuss
the potential role of the IGF-1 system in modulation of longevity, hypothesizing that
the endocrine and metabolic adaptation observed in centenarians and in mammals
during caloric restriction may be a physiological strategy for extending lifespan through a
slower cell growing/metabolism, a better physiologic reserve capacity, a shift of cellular
metabolism from cell proliferation to repair activities and a decrease in accumulation
of senescent cells. Therefore, understanding of the link between IGF-1/insulin system
and longevity may have future clinical applications in promoting healthy aging and in
Rehabilitation Medicine.
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INTRODUCTION
Aging is defined as a physiological decline of biological functions in the body with a progressive
decline or loss of adaptation to internal and external damaging. In humans the aging phenotype is
extremely heterogeneous and can be described as a complex mosaic resulting from the interaction
of several stochastic and environmental events, genetic, and epigenetic alterations accumulated
throughout the lifetime. Despite its enormous complexity, the molecular basis of aging is limited to
few highly evolutionarily conserved biological mechanisms responsible for body maintenance and
repair (1).
During the last 3 decades one of themost discussed topics in gerontology is the role of the growth
hormone (GH)/insulin-like growth factor-1 (IGF-1)/insulin system in the regulation of longevity.
Accumulating evidence suggests that this pathway plays an essential role in the pathogenesis of
several age-related diseases including cancer, dementia, cardiovascular, and metabolic diseases
(2–4).
In animal models it was shown that down-regulation of the GH/IGF-1/insulin system
significantly prolongs the lifespan. However, in humans data are contradictory (5, 6).
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FIGURE 1 | Pleiotropic effects of IGF-1 on health status.
This review describes the latest advances in the research of
the IGF-1 system and modulation of longevity, hypothesizing
that the endocrine and metabolic adaptation observed in
centenarians and in mammals during caloric restriction may be
a physiological strategy for extending lifespan through a slower
cell growing/metabolism, a better control in signal transmission
and physiologic reserve capacity and a decrease in accumulation
of senescent cells. A review of the literature was conducted using
PubMed database with the following keywords: “IGF-1” or “IGF-
I” and “longevity.” The search included articles published in the
English language between January 2008 and August 2018.
IGF-1 SYSTEM AND LONGEVITY IN
ANIMAL MODELS
IGF-1 system has several pleiotropic effects on biological aging
(Figure 1). IGF-1 plays a relevant role in fetal development,
growth during childhood and adolescence, and adult tissue
homeostasis. In addition, IGF-1 seems to have atheroprotective
actions, neural protective, and insulin-like effects (at high
concentrations) and to regulate skeletal metabolism and muscle
regeneration. Nevertheless, IGF-1 is a main risk factor in several
tumors due to its potent proliferative activity, mainly through the
modulation of cell cycle, apoptosis, and cell survival (7–9). Most
of these effects are mediated through the interaction with insulin
receptor substrate (IRS)-1 and-2 and the modulation of the
PI3K/AKT/ mammalian target of rapamycin (mTOR) pathway
(Figure 2).
Several preclinical studies reported that mutation in genes
controlling the GH/IGF-1/insulin signaling pathway can
significantly increase lifespan in both invertebrate and vertebrate
animal models (5, 6).
Invertebrate Models
In invertebrates, the insulin/IGF-like cascade is regulated by
several peptides, able to interact with a single, common
insulin/IGF-1-like receptor.
In the nematode Caenorhabditis elegans the insulin/IGF-
like pathway consists of several proteins encoded by the genes
daf-2 (insulin/IGF-1 receptor-like protein), age-1 (encoding the
catalytic subunit of PI3K), akt-1, akt-2, pdk-1, sgk-1 (serine-
threonine kinases), daf-16 (forkhead transcription factor and the
major target of insulin-like signaling in Caenorhabditis elegans),
skn-1 (oxidative-stress-responsive transcription factor) and daf-
18 (PTEN, a phosphatase, involved in inhibition of the AKT
signaling pathway). The reduced activity of daf-2, age-1, akt-
1, akt-2, pdk-1, sgk-1 genes were shown to downregulate this
pathway, and the animals with these mutations were reported to
age more slowly and to have an increased lifespan up to 300%.
In contrast, the stimulation of the insulin/IGF-like pathway
decreases the lifespan of nematodes (10, 11).
In the fruit fly Drosophila melanogaster the insulin/IGF-
like signaling consists of the dINR (Insulin /IGF-1 receptor-
like protein), the insulin receptor substrate CHICO, the PI3K
Dp110/p60, and the PI3K target PKB (akt-1). The flies with
mutation in these genes were reported to have significantly
increased longevity (12, 13).
Surprisingly, the same molecular mechanisms in different
tissues do not influence aging equally. Several studies in
nematodes and fruit flies have suggested that reduced
insulin/IGF-like signaling in nervous and adipose tissues
has the major role in regulation of longevity (14, 15). Although
in invertebrate models it was shown that this cascade is relevant
in the modulation of lifespan, the influence of insulin/IGF-like
signaling on longevity is much more complex in vertebrates,
since they have functionally specific insulin and IGF molecules,
IGF binding proteins (IGFBPs), IGFBP proteases, GH, multiple
receptors and several mechanisms of intracellular signaling with
different tissue specific expression (16).
Vertebrate Models
Several GH/IGF-1 mutant mice have been developed with
different targets. The most relevant models are described
below.
Snell and Ames Mice
Snell and Ames mice are two mouse strains with mutations in
the PIT-1 and PROP-1 genes, respectively (17, 18). Since both
PIT-1 and PROP-1 proteins are required for the differentiation
of pituitary cells that produce GH, prolactin and TSH, both
types of homozygous mutant mice lack all three hormones (18).
Thesemodels have shown remarkable extension of longevity (42–
70% more than wild type mice), enhanced insulin sensitivity
and lower tumor incidence (19, 20). When Ames dwarfs were
exposed to caloric restriction, their lifespan increased even
further (21). Although these animals lack three hormones, it has
been demonstrated that lifespan extension is mainly influenced
by the GH deficiency (22).
Lit/lit Mice
Lit/lit mice are GH-deficient, carrying a mutation in the gene
which encodes the GH-releasing hormone receptor (GHRHR).
These animals were dwarfs, showed increased adiposity, lower
tumor incidence and a lifespan increased by 23–25% (19).
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FIGURE 2 | Schematic and simplified representation of the several components of the IGF-1/PI3K/AKT/mTOR pathway discussed in this review. IGF-1 increases the
activity of AKT protein with relevant effects on cell survival and proliferation, glucose metabolism and protein synthesis.
GH-Releasing Hormone-Knockout (GHRH-KO) Mice
GH-releasing hormone-knockout (GHRH-KO) mice live 43%
(in females) and 51% (in males) longer than wild-type animals
and share many phenotypic characteristics with Ames dwarf
mice, such as enhanced insulin sensitivity, reduction in plasma
triglyceride and cholesterol levels, increase in adiposity, plasma
leptin, and adiponectin levels (23).
The GH-Receptor-Knockout (GHR-KO) Mice
The GH-receptor-knockout (GHR-KO) mice has elevated serum
GH levels and very low IGF-1 levels. Also this strain of mice was
reported to live 38–55% longer than wild-type (24) and showed
attenuation in oxidative stress, as well as a lower and delayed
onset of fatal tumors (25). Similar results were observed in df/KO
mice, crossing GHR-KOmice and Ames dwarfs, that lacked both
GH and GH receptor and maintained extended longevity (26).
Unlike wild siblings and Ames dwarf mice, caloric restriction did
not further enhance longevity of GHR-KO mice, suggesting that
the GH/IGF-1 axis and caloric restriction might have similar or
partly overlapping mechanisms for lifespan prolongation (27).
GH Receptor Antagonism (GHA)
Not all animal models with suppression of GH/IGF-1 system
exhibit an increase in lifespan. The GHAmouse strain is one such
example. GHA, generated by the substitution of one amino acid
(Gly199 Arg in bovine GH), is able to bind the GH receptor with
the same affinity as GH, but does not cause intracellular signaling.
The lifespan of GHA mice was not significantly increased (28).
IGF-1R+/− Mice
While most of the IGF-1 receptor null mice (IGF-1R−/−) die at
birth, the animals heterozygous for a mutated allele of the IGF-1
receptor (IGF-1R+/−) showed very low serum IGF-1 levels, about
10% smaller size and a 33% increased lifespan in females and 16%
in males. However, in this study the wild-type controls lived to
only 19months of age, compromising the interpretation of results
(29). More recent studies evaluating the lifespan in another IGF-
1R+/− line exhibited a mild 5–10% increase in lifespan, but only
in females (30, 31). In addition, the underlying background strain
seems to influence the degree of life extension in several murine
models (32).
A Brain-Specific IGF1-R+/−
A brain-specific IGF1-R+/− mutant lived 9% longer than wild-
type, underling the relevant role of the neural system in the
modulation of longevity (33).
Liver-Specific IGF-1-Disrupted Mice (LI-IGF-1−/−
Mice)
Liver-specific IGF-1-disrupted mice (LI-IGF-1−/− mice) have
very low serum IGF-1 levels and high serum GH levels due
to inactivation of the IGF-1 gene. LI-IGF-1−/− mice exhibited
markedly decreased adiposity and as a result had 25% lower
weight than wild-type mice. Only female LI-IGF-1−/− mice
showed a 16% increase in lifespan compared to that observed in
control mice (34).
Pappa−/− Mice
Pappa−/− mice are the knockout for the pregnancy associated
plasma A (PAPPA) gene, a specific protease for IGF binding
proteins. The mean lifespan of this mouse strain was 38% longer
compared to wild type controls. Pappa−/− mice were dwarfs,
but their serum glucose, insulin, IGF-1 and GH levels were not
different from those of wild-type controls, suggesting that PAPPA
acts mostly at autocrine or paracrine level and providing evidence
for the role of local availability of IGF-1 in the modulation of
longevity. In addition to extended longevity, Pappa−/− mice
showed a lower incidence of tumor development, as well as age
related degenerative lesions (35, 36).
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IRS Disrupted Mice
IRS-1 and -2 are important mediators for insulin, as well as
for IGF-1 signaling. IRS1−/− mice were insulin-resistant, with
a defect in insulin signaling mainly in muscle tissue, about 30%
smaller in size than the wild-type and only in females the lifespan
was 18% longer compared with wild-type animals (37). IRS2−/−
mice were also insulin-resistant, but unlike IRS1−/− mice, they
exhibited defects in insulin signaling in more tissues, including
the liver, the adipose tissues, and skeletal muscles. These mice
developed diabetes, and had a much shorter lifespan than wild-
type and IRS2+/− mice. IRS2+/− mice had improved insulin
sensitivity and an increased lifespan (+18%) compared to wild-
type mice. In addition, brain specific IRS2+/− and IRS2−/− mice
were reported to be insulin resistant, and lived 18 and 14% longer
than wild-type controls, respectively (38).
KLOTHO Modified Mice
Protein KLOTHO inhibits insulin and IGF-1 signaling, possibly
by disrupting receptor/ligand interaction. Mice overexpressing
KLOTHO were reported to have normal size, and males
developed insulin resistance, while lifespan in both males and
females was significantly increased (+18 and+30%, respectively)
(39, 40).
P66shc Disrupted Mice (P66shc−/− Mice)
P66shc is a protein mediating IGF-1 post-receptor signaling by
activating the MAPK pathway. P66shc−/− mice had normal
phenotype, but lived 28% longer than wild-type controls (41).
However, these data were not confirmed in a recent study (42).
The role of GH/IGF-1/insulin signaling in aging and longevity
has been deeply studied through all these animal models.
While in invertebrates the impact of downregulation in the
IGF-1/insulin pathway on lifespan resulted to be clear and
considerable, in murine models this effect was attenuated and
not reproducible in some cases, such as in the IGF-1R+/− and
P66shc−/− mice. However, most of these models showed the
presence of some commonalities among the long-livedmice, such
as reduced circulating IGF-1 and insulin levels and increased
insulin sensitivity, which likely contribute to reduce tumor
incidence, to improve stress resistance and to extend the lifespan.
Genetic alterations able to disrupt IGF-1 system can keep the
animals healthier for longer periods and can postpone or alleviate
some age-related diseases. In this process nervous and adipose
tissues seem to have a relevant role.
Additionally, more data are needed to determine the best time
point during the lifetime for intervention in suppressing IGF-1
system to obtain beneficial effects on lifespan. In igff/f C57Bl/6
mice deficiency in circulating IGF-1, starting at 5 months of
age or earlier, increased lifespan by 15% only in females, with a
reduction in the number of organs exhibiting disease pathology
at the end of life compared to control group. Moreover, late-
life IGF-1 deficiency (15 months) reduced cancer risk but had
no beneficial effects on lifespan (43). These data underline the
importance of IGF-1 deficiency when started early in life for
increasing longevity. On the other hand, Mao et al. (44) recently
reported that late treatment of 18-months old CB6F1 mice with
an anti-IGF-1 receptor monoclonal antibody prolonged lifespan
by 9% in females and improved several aspects of healthspan.
IGF-1 SYSTEM IN LONG-LIVED
INDIVIDUALS
Centenarians are considered the best human model to study
biological determinants of longevity having reached the very
extremes of the human lifespan (45).
Several studies compared circulating insulin and IGF-1 levels
in centenarians with those of younger controls (46).
Metabolic age-dependent remodeling is a physiological
process occurring in the whole population. Aging is frequently
associated with a decline in glucose tolerance secondary to
an increased insulin resistance (47), but an exception occurs
in long-lived people. Paolisso et al. (48) found that insulin
resistance increased with aging and declined in subjects older
than 90 years living in Southern Italy. Indeed, long-lived subjects
showed a higher insulin sensitivity and a better preservation of
beta-cell function than younger subjects. Such difference was
also independent of the main anthropometric and metabolic
confounders. Centenarians had a lower 2-h plasma glucose
concentration than that aged subjects (mean age 78 years)
during oral glucose tolerance test. In centenarians insulin-
mediated glucose uptake was greater than in aged controls
during euglycemic glucose clamp, supporting a preserved glucose
tolerance and insulin action in this long-lived group (49, 50).
Similar results, supporting a better insulin sensitivity, were
observed in other long-lived populations (51, 52).
Furthermore, centenarians showed a preserved insulin action
not only on the glucose metabolism but also on adipose tissue.
In fact, insulin infusion is normally associated with inhibition of
lipolysis and thus to a significant decline in plasma free fatty acid
and triglyceride concentrations. In centenarians the inhibitory
activity of insulin on lipolysis was stronger than that of controls
(mean age 78 years) (50). It is noteworthy that centenarians
compared to aged controls have also a lower sympathetic tone
which might be due to a better insulin action and thus, to a low
fasting plasma insulin levels (53, 54).
Data on IGF-1 system in relation to longevity are still
controversial in long-lived subjects (46). Paolisso et al. (55)
described an increased plasma IGF-1/IGFBP-3 ratio in healthy
centenarians compared to elderly subjects. They hypothesized
that this elevated ratio was indicative of a higher IGF-1
bioavailability which contributed to the improved insulin action
in centenarians. In contrast, Bonafè et al. (56) reported that
subjects with at least an A allele of the IGF-1 receptor gene (G/A,
codon 1013) had low levels of free plasma IGF-1 and were more
represented among long-lived people. Arai et al. (57) described
relatively low levels of serum IGF-1 in a population of Japanese
centenarians. In this population the lowest tertiles of both IGF-1
and IGFBP-3 were associated with increased mortality (58).
These conflicting results probably reflect the complexity of
the IGF-system and ethnic differences in enrolled populations.
In addition, centenarians have often been compared to a control
group of younger subjects. Therefore, in most of these studies
Frontiers in Endocrinology | www.frontiersin.org 4 February 2019 | Volume 10 | Article 27
Vitale et al. Role of IGF-1 System in the Modulation of Longevity
it was not possible to conclude if IGF-1 differences between
both groups were related to a different lifespan or reflected a
physiological age-dependent IGF-1 decline. Indeed, there are
several limitations to study centenarians: (1) low prevalence (1
centenarian per 5–10.000 inhabitants), (2) presence of frailty due
to extreme age (almost 95% of centenarians have at least 1 frailty
criterion), (3) lack of a control group of the same age (45, 59).
Due to these limitations, this human model is unsuitable to study
age-dependent variables that may be involved in the modulation
of the lifespan.
Centenarians’ offspring represent another interesting model
to define relevant factors involved in human longevity and
healthy aging. A concordant set of observations in different
countries suggest that centenarian’s offspring are healthier than
members of the same demographic cohorts (51, 60, 61) and
biologically (epigenetically) younger than their chronological age
(62). Overall, these studies indicate that relatives of centenarians
have a high probability for living longer and in good health
(60, 63). In addition, studying centenarians’ offspring has
the relevant advantage of the availability of an appropriate
demographically matched control group, consisting in age-
matched offspring having both parents born in the same birth
cohort of centenarians, but dead before the threshold age over
which subjects were classified “long-lived.” This strategy is crucial
for avoiding cohort effects. Therefore, centenarians’ offspring
model can overcome some limitations that are found in the
study of centenarians (rarity, frailty and lack of an appropriate
control) (60).
In few studies the IGF-1/insulin system has been characterized
in centenarians’ offspring and an appropriate matched control
group.
We have evaluated circulating IGF-1 bioactivity, measured by
an innovative IGF-1 Kinase Receptor Activation (KIRA) Assay
in centenarians, centenarians’ offspring and offspring matched-
controls. Centenarians and centenarians’ offspring had relatively
lower circulating IGF-1 bioactivity compared to controls.
Interestingly IGF-1 bioactivity in centenarians’ offspring was
inversely associated to insulin sensitivity (51).
Suh et al. (64) evaluated serum IGF-1 levels in Ashkenazi
Jewish centenarians’ offspring and in age-matched controls.
Female centenarians’ offspring had 35% higher serum IGF-1
levels than that controls. This difference may represent a
compensatory response to reduced IGF-1 receptor signaling.
Indeed, female offspring showed shorter stature than controls.
In addition, an overrepresentation of heterozygous mutations in
the IGF-1 receptor gene together with relatively high serum IGF-
1 levels and weakened activity of the IGF-1 receptor has been
described in Ashkenazi Jewish centenarians compared to controls
without familial longevity.
In order to study longevity, other authors characterized
these pathways in nonagenarian siblings and their offspring.
In the Leiden Longevity Study, 421 families were recruited
consisting of at least two long-lived Caucasian siblings, their
offspring and partners of the offspring as control. In these
populations serum glucose, insulin and triglycerides were the best
biomarker of healthy aging (glucose and insulin low levels were
considered healthy) (65). Nonagenarians in the lowest circulating
IGF-1/IGFBP-3 ratio were associated with a better survival (66).
The offspring of familial nonagenarians exhibited a better insulin
sensitivity compared to their partner, while similar non-fasted
serum levels of IGF-1 and IGFBP-3 were observed between both
groups (67). Interestingly, 24-h total GH secretion was 28% lower
in offspring compared with controls (68).
Another approach adopted to study longevity in humans
consists in the selection of familial components of exceptional
longevity and healthy aging, based on strict criteria, such as the
Family Longevity Selection Score adopted in Long Life Family
Study. These families enriched for exceptional life expectancy
were compared to controls without family history of longevity
(69). In this population circulating IGF-1 levels resulted to be a
valid age-related biomarker (70).
In support of the potential role of the GH/IGF-1/insulin
system in the human longevity, there are many genetic studies.
Indeed, several genetic loci have been identified to be associated
with circulating IGF-1 and IGFBP-3 levels and potentially able to
affect aging (71). A genome-wide association analysis performed
in nonagenarians and a population of subjects <60 years of
age, showed a clear association between genetic variation of
genes involved in insulin/IGF-1 pathway and human longevity
(72). In a prospective study of older people, females with a
genetic profile suggestive of a decreased insulin/IGF-1 signaling
activity, exhibited a longer survival (73). In four independent
cohorts of long-lived individuals it has been recently described
a linear increased prevalence of GH receptor exon 3 deletion (d3-
GHR) homozygosity with age. The presence of d3/d3 genotype
increased life expectancy by about 10 years (74).
IGF-1 SYSTEM AND CALORIC
RESTRICTION
One of the most robust striking observations in the biology of
aging is the capability of caloric restriction to prevent or delay
several age-related diseases and to increase lifespan in mammals
(75–78). The biological mechanisms of this phenomenon are
not completely clear, but it has been suggested a potential
involvement of relevant alterations in energy metabolism,
endocrine system and oxidative damage.
Caloric restriction instigates numerous hormonal changes.
In rodents caloric restriction without malnutrition suppressed
circulating IGF-1 and insulin levels in proportion to the level
of restriction, increased insulin sensitivity and resistance to
stress and toxicity, and reduced the cancer risk (79, 80).
Interestingly, most of these characteristics observed in wild
type mice during caloric restriction resemble those reported
in mice that are long-lived due to genetic disruption of the
GH/IGF-1/insulin signaling, as previously described. In humans,
randomized clinical trials showed that caloric restriction does not
attenuate serum IGF-1 levels unless protein intake is reduced
(81, 82). However, a recent meta-analysis, evaluating the effect
of dietary restriction on well-recognized biomarkers of healthy
aging, showed a decrease in circulating IGF-1 levels in humans
(83). In addition, during caloric restriction skeletal muscle
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transcriptional profile showed a suppression of local insulin/IGF-
1 pathway inducing a younger transcription profile (84).
Other circulating hormonal changes, such as decreased
insulin, thyroid hormones and leptin levels, and increased
adiponectin levels and insulin sensitivity have been observed
during dietary restriction (85, 86). This hormonal adaptation
may have a relevant role in extension of lifespan through several
mechanisms:
1) Reducing metabolic rate, cell proliferation, and oxidative stress.
In fact, IGF-1 is a potent growth factor and thyroid hormone
is a potent stimulator of basal metabolic rate and oxidative
metabolism. In addition, transcriptional patterns suggest that
chronic moderate caloric restriction in adult individuals
retards the aging process by shifting cellular metabolism from
growth to maintenance and repair activities (84).
2) Decreasing the accumulation of senescent cells. Cellular
senescence has been demonstrated to be a key mediator
of aging (87). Over time protein homeostasis declines
and damage accumulates. Interestingly, it is possible to
delay several age-related diseases through attenuating the
accumulation of senescent cells (88, 89). Normally the mTOR
pathway is activated by several signals, including nutrients,
IGF-1 and insulin (Figure 2). The down-regulation of this
pathway, reported after caloric restriction, increased lifespan
in several organisms. This effect seems to be secondary to
an up-regulation of autophagy, a cytoprotective self-digestive
process. In fact, autophagy is a cellular recycling process that
can remove aged or damaged cellular components preventing
the accumulation of senescent cells (90, 91).
3) Counteracting inflammaging. In both animals and humans
dietary intervention can delay the aging process by
attenuating low-grade inflammatory status (83, 92). The
mechanisms underlying the anti-inflammatory activity
of dietary restriction are not well-defined. It has been
hypothesized that this effect is due to the reduction in fat mass
and pro-inflammatory adipokines, and to an improvement
of intestinal barrier integrity observed during dietary
intervention (93, 94).
Interestingly, the endocrine biochemical profile observed in
subjects during caloric restriction is comparable to that reported
in centenarians, supporting a potential role of the endocrine
system in the modulation of lifespan. In addition to an increase
in insulin sensitivity and a decrease in plasma/serum IGF-
1 levels, several studies showed an increase in circulating
adiponectin levels and a reduction in circulating leptin and
thyroid hormones levels in long-lived people compared to
younger subjects (Table 1).
Adipose tissue is an endocrine organ producing several
cytokines involved in relevant processes, such as the energy
metabolism, lipid, and glucose homeostasis and modulation
of inflammatory response. Visceral adipose tissue has a main
role in the development of metabolic diseases (95). Aging is
associated with an increase in fat mass and a redistribution of
adipose tissue, characterized by loss of peripheral subcutaneous
fat and accumulation of visceral fat. In elderly, alterations in
the secretion, synthesis and function of the adipokines have
TABLE 1 | Endocrine biochemical profile observed after caloric restriction and in
centenarians compared to younger subjects.
Endocrine parameters Caloric restriction Centenarians
IGF-1 =/↓* ↓
Insulin ↓ ↓
Insulin sensitivity ↑ ↑
Adiponectin ↑ ↑
Leptin ↓ ↓
Triiodothyronine (T3) ↓ ↓
↓, decrease; ↑, increase; =, no change; *more evident in murine models.
been described, probably due to an unbalance in the function,
proliferation, size, and number of adipose cells (86). Adiponectin
is an insulin sensitizing, anti-inflammatory and anti-atherogenic
cytokine. Adiponectin circulates in the blood in several forms:
trimer, hexamer, high molecular weight (HMW) multimer,
and globular adiponectin (a proteolytically cleaved form). The
HMW multimer is believed to be the more active form of
adiponectin at protecting against insulin resistance and diabetes
(96). Circulating adiponectin is independently and negatively
related to facets of the metabolic syndrome, including insulin
resistance, body weight, blood pressure, and serum lipids. Leptin
is mainly produced in the subcutaneous and to a lesser extent
in the visceral white adipose tissue. This cytokine regulates
food intake, energy expenditure and atherogenesis. Leptin boosts
weight loss by reducing appetite and stimulating metabolic rate
and has pro-inflammatory properties (97).
Several studies reported that centenarians have higher
plasma adiponectin and lower leptin concentrations than
younger controls (53, 98–102). All forms of adiponectin
were significantly increased in centenarians, but the HMW
multimer was markedly higher (99). In centenarians the high
adiponectin concentrations resulted to be independent of
BMI, renal or cardiovascular function and were associated
with a favorable metabolic phenotype (higher HDL-C, lower
hemoglobin A1c, insulin, HOMA-IR and triglycerides) (98,
99). Increased adiponectin levels were also detected in the
offspring of the long-lived subjects (older than 95 years)
(103).
A decrease in thyroid hormones levels seems to be peculiar
in centenarians. Mariotti et al. (104) reported that healthy
centenarians had lower serum TSH and FT3 levels and higher
serum rT3 levels compared with that observed in other control
groups. In another Italian population of centenarians total T4
values were lower than normal range in 60% of examined
subjects (105). Baranowska et al. reported that serum T3 levels
in centenarians were lower compared with that observed in early
elderly and young women (52). We have recently characterized
thyroid function profile in an Italian cohort of 672 subjects (range
52–113 years old). An age-dependent decrease in FT3 level and
FT3/FT4 ratio has been observed, while FT4 and TSH increased
with aging (106). In Chinese centenarians’ families a decline
in thyroid function (high TSH and low FT3 concentrations)
appears to be associated with age, and this phenotype is heritable
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(107). Corsonello et al. (108) found in relatives of centenarians
(offspring or nieces/nephews) lower comorbidities, FT3, FT4,
and TSH levels than age-matched controls who were not relatives
of centenarians. In another Italian population lower plasma level
of FT4 were observed in centenarians’ offspring compared to
age-matched controls (60).
In general, centenarians are lean (109) and follow healthy
nutritional habits but without a calorie-restricted diet (110).
Similarly to subjects during caloric restriction, a slower cell
growing/metabolism, a better control in signal transmission and
an enhanced autophagy have been observed in centenarians.
Through a genome-wide DNA methylation analysis in
centenarians and their offspring, we have identified epigenetically
modulated genes and pathways potentially involved in the
process of aging and longevity. Our results suggest that a
better preservation of DNA methylation status, a slower cell
growing/metabolism and a better control in signal transmission
through epigenetic mechanisms characterized these populations
(111). Centenarians have a preserved bioenergetic function
through a mitochondrial hypertrophy that can recompense for
functional defects (112). In addition, healthy centenarians have
high levels of autophagy, as indicated by higher serum beclin-1
levels compared with both young patients with myocardial
infarction and healthy controls (113). An increase in autophagic
activity has been also observed in subjects belonging to families
with exceptional longevity (114).
A relevant divergence occurs concerning the inflammatory
status, which is attenuated in subjects after caloric restriction
(115, 116) and high in centenarians (117–119). With aging
a state of low-grade and chronic inflammatory condition
(called inflammaging) and an increased prevalence of several
diseases have been observed, such as cardiovascular disease,
atherosclerosis, tumors, cognitive impairment, osteoarthritis,
and diabetes (120, 121). Therefore, attenuation of chronic
inflammatory status after caloric restriction represents a
beneficial effect. Centenarians show signs of inflammaging but
at the same time seem to be spared from its deleterious
consequences. This apparent paradox can be explained by
the fact that centenarians possess a complex and peculiar
balancing between pro-inflammatory and anti-inflammatory
factors, resulting in a slower, more limited and balanced
development of inflammaging, in comparison with elderly, who
are characterized by an inappropriate response to counteract
chronic inflammation (120, 121).
These findings suggests common mechanisms to increase
lifespan and to delay age-related diseases adopted in centenarians
and in mammals following a calorie-restricted diet.
AUTHOR’S OPINION
Preclinical models have provided a great insight into the aging
process with consistent data considering the role of the GH/IGF-
1/insulin system in the modulation of lifespan. While it is
well known that enhanced insulin sensitivity and low insulin
levels are associated with an improved survival, there are several
evidences showing that attenuation of the GH/IGF-1 axis may
have beneficial effects in extending lifespan in humans. However,
it is still unknown which are the optimal IGF-1 levels during
life to live longer and healthier. In addition, IGF-1 receptor
sensitivity and activation of the post-receptor pathway were
not evaluated in the majority of the study enrolling long-
lived subjects. Therefore, it is not possible to define the real
activation status of the IGF-1 receptor signaling through themere
dosage of circulating IGF-1 levels. This renders more difficult
the identification of pharmacological or environmental strategies
targeting this system for extending lifespan and promoting
healthy aging. A comprehensive understanding of these aspects
remains a major challenge for uncovering interventions to slow
human aging and to adopt in Rehabilitation Medicine. Future
studies should evaluate the functional status of IGF-1 receptor
signaling, also through transcriptional profiling and functional
network analyses concerning IGF-1 regulated genes, in long-lived
subjects.
CONCLUSIONS
Striking similarities have been described concerning endocrine
profile between centenarians and subjects after a calorie-
restricted diet. The endocrine andmetabolic adaptation observed
in both models may be a physiological strategy to increase life
span through a slower cell growing/metabolism, a slower loss
of physiologic reserve capacity, a shift of cellular metabolism
from cell proliferation to repair activities and a decrease in
accumulation of senescent cells. These mechanisms seem to be,
at least in part, mediated through the modulation of the GH/IGF-
1/insulin system.
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